- Home
- QURE vs XPEL Comparison
QURE vs XPEL Comparison
Compare QURE & XPEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QURE | XPEL |
|---|---|---|
| Founded | 1998 | 1999 |
| Country | Netherlands | United States |
| Employees | 248 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2013 | 2019 |
Fundamental Metrics
Financial Performance| Metric | QURE | XPEL |
|---|---|---|
| Price | $19.16 | $47.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 1 |
| Target Price | $45.00 | ★ $56.00 |
| AVG Volume (30 Days) | ★ 1.4M | 168.5K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.67 | 12.12 |
| EPS | N/A | ★ 1.85 |
| Revenue | $13,107,000.00 | ★ $476,200,000.00 |
| Revenue This Year | $126.12 | $12.64 |
| Revenue Next Year | $200.43 | $11.98 |
| P/E Ratio | ★ N/A | $25.75 |
| Revenue Growth | N/A | ★ 13.27 |
| 52 Week Low | $8.73 | $29.14 |
| 52 Week High | $71.50 | $55.91 |
Technical Indicators
Market Signals| Indicator | QURE | XPEL |
|---|---|---|
| Relative Strength Index (RSI) | 57.66 | 63.41 |
| Support Level | $13.46 | $31.55 |
| Resistance Level | $25.66 | $49.58 |
| Average True Range (ATR) | 1.26 | 1.39 |
| MACD | 0.24 | 0.05 |
| Stochastic Oscillator | 64.47 | 60.74 |
Price Performance
Historical ComparisonAbout QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
About XPEL XPEL Inc.
XPEL Inc is a supplier of protective films, coatings, and related services principally to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from Product, which includes Paint protection film and Window film. The company derives revenue from Service, which includes Software, Cutbank credits, and Installation labor. The majority of revenue is derived from the United States.